A clinical trial of empagliflozin for heart failure with preserved ejection fraction in patients with NTproBNP levels ≥ 300 pg/mL and limited physical activity demonstrated a significant reduction in heart failure recurrence [4]. The gene discussed is NPPB; the disease is heart failure.